Biochemically, KRASG12R is deficient in activating the PI3K-AKT pathway (46), and targeting this mutation in pancreatic cancer may require strategies that differ from those used to inhibit KRASG12Dand KRASG12V. Here, AKT1 is linked to familial pancreatic carcinoma.